Building REsilience against MEntal illness during ENDocrine-sensitive life stages
Acronym
Re-MEND
Description of the granted funding
Mental illnesses represent a huge burden for society, the economy, and the aMental illnesses represent a huge burden for society, the economy, and the affected individuals. To significantly increase citizens? mental health, today?s symptom-based diagnoses need to be complemented by biological criteria accounting for individual and sex differences. Furthermore, early detection and prevention measures need to be improved. RE-MEND addresses the current gaps and challenges with an interdisciplinary approach by: i) focussing on four critical life stages in which an individual?s susceptibility to mental illness is strongly influenced by changes in endocrine signalling, including sex hormones, namely early life, puberty, peripartum, and transition into old age; ii) integrating data from large population-based longitudinal cohort studies allowing for discovery of risk and protective factors as well as biological patterns that influence mental states in the general population across these life stages; iii) complementing epidemiological with experimental studies to establish correlative and causative links leading to mechanistic understanding; iv) using advanced biostatistics as well as machine learning and artificial intelligence for data integration and biomarker and drug target discovery; v) combining the biological approaches with communication science studies to efficiently translate its results to societal impact. Ultemately, RE-MEND will result in: i) Significantly increased mental health literacy among stakeholders and citizens; ii) Validated biomarkers for assessing mental health state and its predisposition as well as more accurate diagnoses and personalised preventive and therapeutic measures; iii) Recommendations for early detection, better prevention, and drug design strategies to protect vulnerable individuals from mental illness in sensitive life stages; and iv) strategies on how these advances can be used to decrease stigma and increase prevention behaviour.
Show moreStarting year
2023
End year
2027
Granted funding
MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV (DE)
25 000 €
Participant
FONDAZIONE HUMAN TECHNOPOLE (IT)
361 675.72 €
Third party
UNIVERSITA DEGLI STUDI DI MILANO (IT)
636 902.28 €
Participant
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US)
154 303 €
Participant
INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH BANGLADESH (BD)
243 675 €
Participant
FONDAZIONE TELETHON (IT)
593 750 €
Participant
UNIVERSITAET BIELEFELD (DE)
686 675 €
Participant
UNIVERSIDADE DE AVEIRO (PT)
445 750 €
Participant
UNIVERSITY OF ROCHESTER (US)
56 250 €
Participant
KARLSTADS UNIVERSITET (SE)
743 118 €
Participant
UMEA UNIVERSITET (SE)
495 442 €
Participant
KLINIKUM DER UNIVERSITAET ZU KOELN (DE)
771 762 €
Participant
STOCKHOLMS UNIVERSITET (SE)
330 272 €
Participant
UNIVERSITY OF ULSTER (UK)
Participant
VETENSKAP & ALLMANHET, VA (SE)
250 156 €
Participant
KAROLINSKA INSTITUTET (SE)
949 686.75 €
Participant
UPPSALA UNIVERSITET (SE)
3 874 595.5 €
Coordinator
Amount granted
10 868 221 €
Funder
European Union
Funding instrument
HORIZON Research and Innovation Actions
Framework programme
Horizon Europe (HORIZON)
Call
Programme part
Health (11673 Health throughout the Life Course (11689 )
Topic
Towards a molecular and neurobiological understanding of mental health and mental illness for the benefit of citizens and patients (HORIZON-HLTH-2021-STAYHLTH-01-02Call ID
HORIZON-HLTH-2021-STAYHLTH-01 Other information
Funding decision number
101057604